Gemmer Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Gemmer Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-800	Closed	-$2K	–	1395
2021 Q2	$2K	Hold	800	–	–	﹤0.01%	1422
2021 Q1	$4K	Hold	800	–	–	﹤0.01%	1171
2020 Q4	$3K	Buy	+800	New	+$2.87K	﹤0.01%	1239

Other funds holding PLX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Gemmer Asset Management's PLX Position: Q3 2021 in Review

Gemmer Asset Management sold out of Protalix BioTherapeutics (PLX) in Q3 2021, closing a stake of 800 shares — an estimated $2K sold.

Gemmer Asset Management first reported a position in PLX in Q4 2020 and held it in 3 quarters. The position peaked at $4K in Q1 2021. 34 funds tracked by Wall St. Rank hold PLX as of Q3 2021.

Gemmer Asset Management reported no remaining Protalix BioTherapeutics position as of Q3 2021 after selling out during the quarter.
Gemmer Asset Management sold 800 Protalix BioTherapeutics shares in Q3 2021, an estimated $2K.
Gemmer Asset Management first reported a position in Protalix BioTherapeutics in Q4 2020 and held it in 3 quarters.
Gemmer Asset Management's Protalix BioTherapeutics position peaked at $4K in Q1 2021.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2021.

Based on Gemmer Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.